CompletedPhase 3NCT00945906
An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Studying Congenital factor XIII deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Program Director, Clinical R&DCSL Behring
- Intervention
- FXIII Concentrate (Human) (FXIII)(biological)
- Enrollment
- 61 enrolled
- Eligibility
- All sexes
- Timeline
- 2009 – 2011
Study locations (25)
- Study Site, Dothan, Alabama, United States
- Study Site, Oakland, California, United States
- Study Site, Orange, California, United States
- Study Site, San Francisco, California, United States
- Study Site, Stockton, California, United States
- Study Site, Fort Myers, Florida, United States
- Study Site, Miami, Florida, United States
- Study Site, St. Petersburg, Florida, United States
- Study Site, New Orleans, Louisiana, United States
- Study Site, Boston, Massachusetts, United States
- Study Site, Ann Arbor, Michigan, United States
- Study Site, Detroit, Michigan, United States
- Study Site, Kansas City, Missouri, United States
- Study Site, Las Vegas, Nevada, United States
- Study Site, Lebanon, New Hampshire, United States
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00945906 on ClinicalTrials.gov